Ipamorelin in Mexico — guide and where to buy

Introduction

Ipamorelin is one of the growth-hormone secretagogue peptides with the most prominent recent preclinical literature, studied for its selective profile of action at the growth-hormone-secretagogue receptor. In the Mexican research peptide market, demand has grown alongside that of other secretagogues, which coexists with legitimate supply and resellers without analytical documentation.

This guide describes the structure of the compound, the nature of the available evidence, handling considerations for a receiving laboratory, and concrete steps to evaluate a vial on receipt. The focus is strictly technical and research-oriented.

What is ipamorelin

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It acts as a selective agonist of the ghrelin receptor, also known as the growth-hormone-secretagogue receptor (GHS-R), and is described as a secretagogue that induces the release of growth hormone from the pituitary. Its CAS number is 170851-70-4.

The feature that distinguishes ipamorelin from older, less-selective secretagogues is that, in the described models, growth-hormone release is not accompanied by the rise in cortisol, prolactin, and ACTH characteristic of those compounds. Its molecular weight is approximately 711.85 Da, a value relevant for identity confirmation by mass spectrometry.

Preclinical evidence

Available evidence concentrates in animal models and in vitro systems. The original characterization, published by Raun and colleagues, described ipamorelin as the first selective growth-hormone secretagogue and documented its release profile in preclinical models ^[1].

• Preclinical models of growth-hormone release from the pituitary ^[1].
• Selectivity profile at the GHS-R relative to less-selective secretagogues ^[1].
• Absence of a concomitant rise in cortisol and prolactin in the described models ^[1].
• In vitro studies of receptor binding and second-messenger activation.

The most-cited primary reference is Raun K, Hansen BS, Johansen NL, et al. «Ipamorelin, the first selective growth hormone secretagogue.» Eur J Endocrinol. 1998;139(5):552–561 ^[1], available on PubMed (https://pubmed.ncbi.nlm.nih.gov/9849822/). Extrapolation of these findings to humans is not supported by an equivalent clinical body of work, and ipamorelin holds no FDA, EMA, or COFEPRIS approval for human use.

Research considerations

For a laboratory incorporating ipamorelin into a protocol, operational considerations include presentation form, storage conditions, and study design. The standard presentation is sterile lyophilized in borosilicate vials, typically 5 mg or 10 mg per vial. Reconstitution is performed with the diluent defined in the lab SOP, usually bacteriostatic water, depending on the experimental model.

• Store the lyophilized vial at −20 °C, protected from light and moisture.
• Reconstitute with sterile bacteriostatic water per the institutional SOP.
• Keep the compound in lyophilized form until the moment of use.
• Protect from light to limit peptide degradation.
• Aliquot the reconstituted solution to avoid repeated thermal cycles.

Study design must comply with applicable animal ethics protocols (NOM-062-ZOO-1999 in Mexico) and be authorized by the institutional committee. Use outside an authorized protocol does not fall within the scientific research framework.

How to evaluate a vial

Evaluating an ipamorelin vial on receipt follows the same criteria as any research peptide, with emphasis on analytical traceability. HPLC purity stated in the COA must be ≥99%, with the chromatogram of the specific lot. Identity by mass spectrometry must show an observed mass consistent with the theoretical molecular weight of the pentapeptide (approximately 711.85 Da).

1. Verify the COA corresponds to the physical lot of the vial received.
2. Confirm HPLC purity ≥99% with attached chromatogram.
3. Confirm identity by MS: observed mass vs. theoretical mass.
4. Review batch traceability from synthesis to the final vial.
5. Inspect the lyophilizate: uniform solid, no particles or moisture.

MX-1 Labs distributes ipamorelin as a research compound from CDMX, with per-batch COA and MS-confirmed identity; the per-batch retention sample is held by the synthesizing lab. For a Mexican laboratory, this combination of analytical documentation and domestic origin simplifies audits and reduces transit times.

Conclusion

Ipamorelin is a compound with preclinical literature oriented toward its selective profile as a growth-hormone secretagogue, but without comparable formal clinical validation. Its incorporation into a research protocol requires robust analytical documentation from the supplier, handling conditions defined in the SOP, and an experimental design authorized by the institutional committee. Supplier choice must rest on verifiable criteria, not commercial messaging.

This article is educational only. Ipamorelin is not a medication or a product for human consumption and is distributed solely as a material for research use only in the laboratory.